Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Pelargonium sidoides is a South African geranium containing gallic acid, ellagitannins, and coumarins that modulate immune responses. The root extract demonstrates strong clinical efficacy for reducing respiratory tract infection symptoms through antimicrobial and immunomodulatory mechanisms.
Origin & History
Pelargonium sidoides is a medicinal plant native to South Africa's Eastern Cape and KwaZulu-Natal regions, traditionally harvested from its roots. Commercial extracts like EPs 7630 (Kaloba®) are produced via hydroalcoholic extraction of dried roots, standardized to contain specific levels of phenolic compounds and coumarins.
Research Narrative (Provisional)
A phase III randomized controlled trial (n=103, PMID: 18005909) demonstrated EPs 7630 extract significantly reduced common cold symptoms compared to placebo, with nearly 80% of patients clinically cured within 10 days. Multiple systematic reviews and meta-analyses, including a Cochrane review (PMID: 24146345), have confirmed efficacy for acute bronchitis and upper respiratory infections, with a feasibility RCT (n=134, PMID: 33514367) supporting larger trials.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Pelargonium sidoides is not consumed as a food or dietary source; it is used exclusively as a medicinal herb, primarily via root extracts (marketed as EPs 7630/Umckaloabo). Therefore, standard macronutrient profiling (calories, protein, fat, carbohydrates, fiber) is not applicable in a dietary context. The pharmacological value resides in its bioactive secondary metabolites: Polyphenolic compounds: The root extract is rich in prodelphinidins (proanthocyanidins/condensed tannins), including gallocatechin and epigallocatechin oligomers, with total proanthocyanidin content estimated at 30–40% of the dry extract weight in standardized preparations. Coumarins: Key unique coumarins include umckalin (7-hydroxy-5,6-dimethoxycoumarin, ~0.06–0.15% of dry root), 6,8-dihydroxy-5,7-dimethoxycoumarin, scopoletin, and 5,6,7-trimethoxycoumarin. These coumarins are considered principal active markers and contribute to immunomodulatory and antibacterial activity. Simple phenolic acids: Gallic acid (~1.5–4% of dry extract), shikimic acid, caffeic acid, and their methyl esters are present and contribute to antioxidant and antimicrobial effects. Benzopyranones: Including umckalin derivatives that are relatively unique to this species within the Pelargonium genus. Minerals and micronutrients: Trace amounts of calcium, magnesium, potassium, iron, and zinc are present in root material, but concentrations are pharmacologically and nutritionally insignificant given the small doses used medicinally (typically 10–30 drops or 10–60 mg extract per dose). Vitamins: No significant vitamin content has been documented. Essential oils: Minor volatile fractions contain sesquiterpenes and aliphatic compounds, but in very low concentrations (<0.1% of root material). Bioavailability notes: The coumarin and proanthocyanidin fractions demonstrate moderate oral bioavailability. The ethanolic extraction process used in EPs 7630 (11% ethanol, drug-to-extract ratio 1:8–10) enhances solubilization of coumarins and low-molecular-weight polyphenols. Prodelphinidins of higher molecular weight (>trimers) have limited gastrointestinal absorption and may exert local mucosal immunomodulatory effects. Umckalin and scopoletin show reasonable absorption and have been detected in plasma after oral dosing in pharmacokinetic studies.
Reported Mechanism (Provisional)
Pelargonium sidoides root extract contains gallic acid, ellagitannins, and coumarins that inhibit viral and bacterial adhesion to respiratory epithelial cells. The bioactive compounds modulate cytokine production, particularly reducing pro-inflammatory IL-6 and TNF-α while enhancing interferon-β secretion. These mechanisms collectively improve mucociliary clearance and strengthen local immune defense in respiratory tissues.
Clinical Narrative (Provisional)
Multiple Phase III randomized controlled trials demonstrate strong efficacy for respiratory infections. A pivotal RCT (n=103) showed 92% greater symptom improvement versus placebo, with 78.8% clinical cure by day 10. Meta-analyses of acute bronchitis studies consistently show significant symptom reduction and shortened illness duration. Evidence quality is robust across respiratory tract infections, with effect sizes typically showing moderate to large clinical benefits.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.